

Confederation of Indian Industry

2nd CII National Biotechnology Conclave 2018

"Driving Inclusive Growth for Indian Bio-economy Vision- 2025" 22 November 2018: India Habitat Center, New Delhi

Program Grid

0830-1000 Hrs	Registration and Tea/ Coffee
1000-1045 Hrs	Inaugural Session
1045-1100 Hrs	Networking Tea
1100- 1200 Hrs	Panel Discussion I: Catalyzing the vaccine industry
	Vaccine industry has earned India a special place in the global arena. Indian vaccine companies have excelled at successfully collaborating with global partners ensuring technology access and product development by adopting innovative technologies. However, there still remains a scope of harnessing the full potential of the sector. This panel aims to discuss the key regulatory policies that builds close synergy between regulators; industry and academia that would help achieve the most efficient health benefits from the best in this industry.
1200- 1300 Hrs	Panel Discussion II: <i>The current state of biosimilars and prospects for the future</i>
	India is poised to be the world's largest hub for manufacturing biological drugs. It's been evident for a decade now that biological drugs are the future of medicine. If we are to realize the full potential of biosimilars to improve people's health, it is essential to encourage public policy and regulatory environment to support research and development that drives biosimilar innovation. We need to assess that how ready are we, to both exploit the opportunities biosimilars offer, and derive the benefits of these new and innovative medicines. The below panel will discuss the current state of biosimilars and strategize the next 10 years plan to accomplish India's dominant position in regulated and RoW markets.
1300- 1400 Hrs	Networking Lunch
1400- 1500 Hrs	Panel Discussion III: Indian bio-agriculture industry as a strategic imperative for future food security
	The Indian agriculture sector remains the backbone of the nation's economy, accounting for 15% of the country's GDP. While the central government has taken a few positive steps to promote the bio-agriculture sector, lack of implementation rigor, and existing bottlenecks in the current regulatory framework have impaired the full potential of biotechnologically engineered and genetically modified foods and crops. This Session proposes to address such regulatory shortcomings and political hurdles that may help India become a more competitive economic player and an influential international participant in this rapidly changing field.



2nd CII National Biotechnology Conclave 2018

"Driving Inclusive Growth for Indian Bio-economy Vision- 2025"

22 November 2018: India Habitat Center, New Delhi

1500 -1515 Hrs Networking Tea 1515-1615 Hrs Panel Discussion IV: Striking gold with the adoption of precision and personalized medicines It is reported that a significantly rising number of middle-class Indians incur losses of around \$23 billion annually in treating or getting tested for noncommunicable diseases. Precision medicine is the most promising economical solution for middle-class Indians. Targeted therapies aim to reduce the costs of hospice stay to markedly reduce overall financial, physical and psychological costs seen with experimental diagnostics treatments. With a projected growth of 25% under the aegis of India's best biotech professionals and diagnosticians, precision medicine is already being practiced in several specialties like oncology, cardiology, psychiatry and diabetology. The purpose of the Session is to brainstorm upon the opportunities and challenges as the Indian healthcare industry transforms towards precision medicine practices. 1615-1730 Hrs Panel Discussion V: Building a future ready biotechnology sector in "Make in India" era Biotechnology is one of the key sectors identified by the government as part of 'Make in India', and the National Biotechnology Development Strategy has provided a strategic roadmap for India's emergence as a global biotech innovation hub with a target of \$100 billion by 2025. This would entail access to adequate capital, quality infrastructure, conducive policy framework and highend talent if India is to build global leadership as a knowledge economy and a potential investment market with research and innovation as its foundation. The Sessions would discuss the strategies for fostering the biotech ecosystem in India with convergence of bioentrepreneurship. 1730 Hrs Close of the Conclave